OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
Lisa Schots, Lynda Grine, Rani Soenen, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 3, pp. 1473-1481
Open Access | Times Cited: 13
Lisa Schots, Lynda Grine, Rani Soenen, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 3, pp. 1473-1481
Open Access | Times Cited: 13
Showing 13 citing articles:
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Personalising biologic therapy in psoriasis: Development, validation and user-testing of a precision dosing dashboard
Charlotte M. Thomas, David Baudry, Zehra Arkir, et al.
Journal of Investigative Dermatology (2025)
Open Access
Charlotte M. Thomas, David Baudry, Zehra Arkir, et al.
Journal of Investigative Dermatology (2025)
Open Access
Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
Karine Rodríguez-Fernández, Víctor Mangas‐Sanjuán, Matilde Merino‐Sanjuán, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 654-654
Open Access | Times Cited: 17
Karine Rodríguez-Fernández, Víctor Mangas‐Sanjuán, Matilde Merino‐Sanjuán, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 654-654
Open Access | Times Cited: 17
Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study
David Gleeson, Maneeha Naveed, Lucy Moorhead, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 243-251
Open Access | Times Cited: 2
David Gleeson, Maneeha Naveed, Lucy Moorhead, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 243-251
Open Access | Times Cited: 2
Rani Soenen, Lisa Schots, Ziyi Wang, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8, pp. 1555-1565
Open Access | Times Cited: 2
Blocking interleukin‐17 in psoriasis: Real‐world experience from the PsoPlus cohort
Lisa Schots, Rani Soenen, Brigitte Blanquart, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 698-710
Open Access | Times Cited: 11
Lisa Schots, Rani Soenen, Brigitte Blanquart, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 698-710
Open Access | Times Cited: 11
Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients
Justin M. Eichinger, Divya M. Shan, Jonathan D. Greenzaid, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 249-262
Closed Access | Times Cited: 1
Justin M. Eichinger, Divya M. Shan, Jonathan D. Greenzaid, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 249-262
Closed Access | Times Cited: 1
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
Rani Soenen, Zhigang Wang, Lynda Grine, et al.
Clinical and Experimental Dermatology (2022) Vol. 47, Iss. 7, pp. 1324-1336
Open Access | Times Cited: 6
Rani Soenen, Zhigang Wang, Lynda Grine, et al.
Clinical and Experimental Dermatology (2022) Vol. 47, Iss. 7, pp. 1324-1336
Open Access | Times Cited: 6
The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases
Panagiotis-Dimitrios Mingas, Jurij Zdovc, Iztok Grabnar, et al.
Molecules (2021) Vol. 26, Iss. 6, pp. 1787-1787
Open Access | Times Cited: 7
Panagiotis-Dimitrios Mingas, Jurij Zdovc, Iztok Grabnar, et al.
Molecules (2021) Vol. 26, Iss. 6, pp. 1787-1787
Open Access | Times Cited: 7
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1708-1716.e4
Open Access | Times Cited: 2
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1708-1716.e4
Open Access | Times Cited: 2
Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
Lisa Schots, Rani Soenen, Debby Thomas, et al.
JEADV Clinical Practice (2024)
Open Access
Lisa Schots, Rani Soenen, Debby Thomas, et al.
JEADV Clinical Practice (2024)
Open Access
Relationships between Secukinumab Concentrations, Disease Activity, and Il-17a Levels in Psoriasis: A Cross-Sectional Observational Study
K. Zhu, Lu Zhou, Lei Cao, et al.
(2024)
Closed Access
K. Zhu, Lu Zhou, Lei Cao, et al.
(2024)
Closed Access
